Scott Bizily Sells 2,407 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

Key Points

• Scott Bizily, an insider at 4D Molecular Therapeutics, sold 2,407 shares of stock for a total of $19,256, reducing his ownership by 24.06%.
• The company's stock recently opened at $8.39, showing a 0.4% decline, with a market cap of approximately $391.81 million.
• 4D Molecular Therapeutics reported a negative EPS of $(0.98) for the last quarter, missing expectations by 10 cents, while analysts project a price target average of $30.40 for the stock.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 2,407 shares of the stock in a transaction on Tuesday, September 23rd. The stock was sold at an average price of $8.00, for a total value of $19,256.00. Following the completion of the transaction, the insider owned 7,596 shares in the company, valued at approximately $60,768. This represents a 24.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

4D Molecular Therapeutics Stock Down 0.4%

Shares of FDMT opened at $8.39 on Monday. The stock has a market cap of $391.81 million, a P/E ratio of -2.38 and a beta of 2.85. The business's fifty day moving average is $6.33 and its 200 day moving average is $4.58. 4D Molecular Therapeutics, Inc. has a 12-month low of $2.23 and a 12-month high of $11.20.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.52 million. On average, analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on FDMT shares. Roth Capital dropped their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Chardan Capital restated a "buy" rating and issued a $25.00 target price on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Saturday, September 13th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $30.40.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE boosted its stake in 4D Molecular Therapeutics by 49.8% during the fourth quarter. Bank of America Corp DE now owns 384,880 shares of the company's stock valued at $2,144,000 after buying an additional 127,885 shares during the last quarter. ProShare Advisors LLC lifted its stake in shares of 4D Molecular Therapeutics by 30.1% in the 4th quarter. ProShare Advisors LLC now owns 16,369 shares of the company's stock valued at $91,000 after purchasing an additional 3,783 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of 4D Molecular Therapeutics by 196.3% in the fourth quarter. Two Sigma Investments LP now owns 313,993 shares of the company's stock worth $1,749,000 after buying an additional 208,021 shares during the period. Two Sigma Advisers LP raised its holdings in shares of 4D Molecular Therapeutics by 452.0% in the fourth quarter. Two Sigma Advisers LP now owns 126,400 shares of the company's stock worth $704,000 after buying an additional 103,500 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in 4D Molecular Therapeutics by 7.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company's stock worth $247,000 after purchasing an additional 2,925 shares during the period. Hedge funds and other institutional investors own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.